← Drug database

Zometa (zoledronic acid)

Region
🇪🇺 EU
Active substance
zoledronic acid
Company
Phoenix Labs Unlimited Company
Status
Authorised
Therapeutic area
Cancer; Fractures, Bone
CHMP opinion
Thu 14 Dec 2000
EU approval
Tue 20 Mar 2001
Application
EMEA/H/C/000336
ATC
M05BA08
Official record
www.ema.europa.eu

Indication

Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; treatment of tumour-induced hypercalcaemia (TIH); prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced malignancies involving bone; treatment of tumour-induced hypercalcaemia (TIH); prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone; treatment of adult patients with tumour-induced hypercalcaemia (TIH).

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Zometa

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.